Orphans Elahere, Hetronifly & Hympavzi Among Eight New Products Set For EU Approval
Executive Summary
The European Medicines Agency has recommended the pan-EU approval of three rare disease drugs: Pfizer’s Hympavzi, Henlius Biotech’s Hetronify and ImmunoGen’s Elahere in addition to five other new medicines